Product Description
Proguanil is a prophylactic antimalarial drug, which works by stopping the malaria parasite, Plasmodium falciparum and Plasmodium vivax, from reproducing once it is in the red blood cells. It does this by inhibiting the enzyme, dihydrofolate reductase, which is involved in the reproduction of the parasite. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Proguanil)
Mechanisms of Action: DHFR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Australia | Austria | Bangladesh | Belgium | Brazil | Canada | Chile | Colombia | Czech | Denmark | Dominican Republic | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lithuania | Luxembourg | Malaysia | Malta | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Poland | Portugal | Saudi Arabia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Thailand | United Arab Emirates | United Kingdom | United States | Vietnam
Approved Indications: Malaria | Malaria, Falciparum
Known Adverse Events: Abdominal Pain | Dizziness | Headache | Pain Unspecified | Oral Ulcer | Pruritus | Anorexia | Asthenia | Diarrhea
Company: Dstl
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United Kingdom
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Malaria
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| MMV_SMC_19_02 | P1 |
Completed |
Malaria |
2022-03-18 |